The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.
PACT Pharma raised $95 million in Series B financing. Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.
Documentaries, videos and podcasts